P036 | A-AVD VERSUS ABVD IN FIRST-LINE STAGE IV CLASSICAL HODGKIN LYMPHOMA: EFFICACY AND TOXICITY IN A SINGLE CENTER EXPERIENCE

Brentuximab Vedotin combined with AVD (A-AVD) is the new standard for first-line advanced-stage Hodgkin Lymphoma (HL). The ECHELON-1 trial showed improved 7-year PFS (82.3% vs 74.5%) and OS (93.5% vs 88.8%) with A-AVD compared to ABVD. Nevertheless, the enhanced survival outcomes may be accompanied...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	M. Cristante, F. Fallanca, C. Martinenghi, M.C. Quattrocchi, T. Calimeri, P. Angelillo, E. Flospergher, F. Erbella, G. Cassanello, A.J.M. Ferreri, F. Marino
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Ferrata Storti Foundation 2025-09-01
Sarja:	Haematologica
Linkit:	https://haematologica.org/article/view/12533
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!